Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – What’s Next?

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) hit a new 52-week high on Monday. The company traded as high as $98.49 and last traded at $98.3510, with a volume of 309,132 shares changing hands. The stock had previously closed at $93.86.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group lifted their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. The Goldman Sachs Group raised their price objective on Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Finally, Wells Fargo & Company lifted their target price on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.57.

Kiniksa Pharmaceuticals International Stock Up 4.6%

The business’s 50 day simple moving average is $80.46 and its two-hundred day simple moving average is $61.36. The stock has a market cap of $7.66 billion, a P/E ratio of 75.61 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The company had revenue of $285.97 million during the quarter, compared to the consensus estimate of $260.66 million. As a group, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Mark Ragosa sold 36,783 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $92.16, for a total transaction of $3,389,921.28. Following the sale, the chief financial officer directly owned 20,854 shares of the company’s stock, valued at approximately $1,921,904.64. This trade represents a 63.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 220,170 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $93.27, for a total value of $20,535,255.90. Following the sale, the chief executive officer directly owned 780,037 shares in the company, valued at $72,754,050.99. The trade was a 22.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 831,022 shares of company stock worth $77,475,599. Company insiders own 51.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KNSA. Virtus Advisers LLC bought a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $139,000. JW Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at approximately $1,641,000. Russell Investments Group Ltd. raised its stake in shares of Kiniksa Pharmaceuticals International by 1,656.1% during the third quarter. Russell Investments Group Ltd. now owns 61,569 shares of the company’s stock valued at $4,594,000 after acquiring an additional 58,063 shares during the last quarter. Lisanti Capital Growth LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 48.0% during the third quarter. Lisanti Capital Growth LLC now owns 129,250 shares of the company’s stock valued at $9,643,000 after acquiring an additional 41,945 shares during the last quarter. Finally, Jacobi Capital Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter valued at $48,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally.

Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

The company also develops investigational therapies for inflammatory and immune-mediated conditions, including treatments that target pathways involved in immune-cell activity.